Oxford BioTherapeutics (OBT) is focused on the development of targeted antibody-based medicines for oncology. OBT’s strategy is to develop innovative antibody-based cancer drugs, with integrated diagnostics, against novel targets that it has discovered in its unique OGAP® proteomic database. Through its alliances with world leaders in antibody development (see Collaborations), OBT is in an unrivalled position to convert its novel targets into an exciting pipeline of first-in-class therapeutics for the treatment of cancer. OBT’s pipeline will deliver cost-effective medicines to fulfill the major unmet medical need of cancer patients.